All About Salbutamol

Page 54 - Get up to date with the latest news, scores & standings from the Cycling News Community.

What will the verdict in Froome's salbutamol case?

  • He will be cleared

    Votes: 43 34.1%
  • 3 month ban

    Votes: 4 3.2%
  • 6 month ban

    Votes: 15 11.9%
  • 9 month ban

    Votes: 24 19.0%
  • 1 year ban

    Votes: 16 12.7%
  • 2 year ban

    Votes: 21 16.7%
  • 4 year ban

    Votes: 3 2.4%

  • Total voters
    126
It's a meta-analysis.
Yes, and as I noted, the kind of studies it based its conclusion on were already discussed in this thread. What are the imolications of this study? Should salbutamol be banned? No support for that, and that's not going to happen, anyway. Should the permissible amount be raised? More studies would be needed to decide that, and not just studies of its effect, but more importantly, studies correlating dose with urine levels under various conditions.

A major outcome of the Froome case is that WADA emphasized that salbutamol positives have to be decided on a case by case basis, which in effect means they're abandoning any fixed standard urine level. The level will still be there, and a rider exceeding it may have to defend himself, but now the road is more open to doing that. A second implication is the belief--allegedly supported by Froome's samples, but because these data have not been made available, we can't judge that--that outliers can be relatively common.

It seems to me that what's needed much more than evidence of salbutamol's PE effects is better evidence of dose-urine level relationships. That's far more relevant to controlling its use.
 
Last edited:
Reactions: fmk_RoI
No, 1352 was Petacchi's raw value. His adjusted value was 819.

i really don't see that this study concludes anything new. When we were discussing the Froome case upthread, many links were posted of studies showing that salbutamol could improve sprint and strength.
Yes, but the panel was satisfied no adjustment needed to be made for specific gravity. Their reason was specific gravity of the urine is irrelevant to the enantiomer analysis and the analysis was not compatible with an inhaled therapeutic dose of salbutamol. We can only go by the lab procedures and rules applicable at the time. I agree with Fitch though, in retrospect Pettachi should be cleared the same as Froome because of this and Pettachi's was perhaps an inhaled therapeutic dose of salbutamol too.
 
Last edited:
Yes, but the panel was satisfied no adjustment needed to be made for specific gravity. Their reason was specific gravity of the urine is irrelevant to the enantiomer analysis and the analysis was not compatible with an inhaled therapeutic dose of salbutamol. We can only go by the lab procedures and rules applicable at the time. I agree with Fitch though, in retrospect Pettachi should be cleared the same as Froome because of this and Pettachi's was perhaps an inhaled therapeutic dose of salbutamol too.
If you're talking about the CAS decision for Petacchi, yes, but what relevance does this have to your previous incorrect comment that Petacchi's level was about the same as Froome's? Petacchi would not even have had a case that anyone knew about if the current rule about SG had been in force at that time. Whereas that same rule did not help Froome.

I already discussed upthread that there is not a reliable way to distinguish inhaled from oral, and that even if there were, taking an inhaled dose larger than permitted is still doping. The panel wanted to believe Petacchi was not cheating, that's blatantly obvious from reading the decision.

We can only go by the lab procedures and rules applicable at the time.
Obviously, Froome's case was an exception to that.
 
Aerobic flipside to the same meta-analysis
https://bjsm.bmj.com/content/early/2020/08/14/bjsports-2019-100984

Conclusion/implication The present study shows that beta2-agonists do not affect aerobic performance in non-asthmatic subjects regardless of type, dose, administration route, duration of treatment or performance level of participants. The results of the present study should be of interest to WADA and to anyone who is interested in equal opportunities in competitive sports.
 
Reactions: movingtarget

ASK THE COMMUNITY